Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal sumatriptan powder via OptiNose device for acute migraine
2006-005991-41Phase 2Completed
- Sponsor
- OptiNose
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sumatriptan in migraine (3 arms), sponsored by OptiNose. Primary endpoint: Pain-free at 120 minutes. Started Jan 2007; status: completed.
02
Drugs
sumatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on 2006-005991-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005991-41.